{"protocolSection":{"identificationModule":{"nctId":"NCT01436149","orgStudyIdInfo":{"id":"SPD489-322"},"secondaryIdInfos":[{"id":"2011-003018-17","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Takeda","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","officialTitle":"The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant"},"statusModule":{"statusVerifiedDate":"2021-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-10-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-12-23","type":"ACTUAL"},"completionDateStruct":{"date":"2013-12-23","type":"ACTUAL"},"studyFirstSubmitDate":"2011-09-15","studyFirstSubmitQcDate":"2011-09-16","studyFirstPostDateStruct":{"date":"2011-09-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-11-10","resultsFirstSubmitQcDate":"2014-11-10","resultsFirstPostDateStruct":{"date":"2014-11-19","type":"ESTIMATED"},"dispFirstSubmitDate":"2014-08-20","dispFirstSubmitQcDate":"2014-08-20","dispFirstPostDateStruct":{"date":"2014-08-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-05-25","lastUpdatePostDateStruct":{"date":"2021-06-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Shire","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:\n\n* How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?\n* Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant?\n* How much SPD489 should be given to patients with depression who are also taking an antidepressant?\n* How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?"},"conditionsModule":{"conditions":["Major Depressive Disorder"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1262,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Antidepressant + SPD489","type":"EXPERIMENTAL","interventionNames":["Drug: SPD489 (Lisdexamfetamine dimesylate )"]},{"label":"Antidepressant + Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPD489 (Lisdexamfetamine dimesylate )","description":"Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks","armGroupLabels":["Antidepressant + SPD489"],"otherNames":["Vyvanse"]},{"type":"DRUG","name":"Placebo","description":"Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks","armGroupLabels":["Antidepressant + Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","timeFrame":"8 weeks"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks","description":"Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.","timeFrame":"8 weeks"},{"measure":"Percentage of Participants Achieving a 25% Response on the MADRS","description":"The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).","timeFrame":"up to 8 weeks"},{"measure":"Percentage of Participants Achieving a 50% Response on the MADRS","description":"The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).","timeFrame":"up to 8 weeks"},{"measure":"Percentage of Participants Achieving Remission on the MADRS","description":"MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).","timeFrame":"up to 8 weeks"},{"measure":"Mean Change From Baseline Over Time in MADRS Total Score","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","timeFrame":"Baseline and up to 8 weeks"},{"measure":"Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)","description":"The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \\[low amount of symptom\\]) to 3 (representing the least favorable response \\[frequent/intense symptom\\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.","timeFrame":"up to 8 weeks"},{"measure":"Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)","description":"Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.","timeFrame":"up to 8 weeks"},{"measure":"Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)","description":"The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.","timeFrame":"up to 8 weeks"},{"measure":"Clinical Global Impressions - Global Improvement (CGI-I)","description":"Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","timeFrame":"up to 8 weeks"},{"measure":"Columbia Suicide Severity Rating Scale (C-SSRS)","description":"C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.","timeFrame":"up to 8 weeks"},{"measure":"Amphetamine Cessation Symptom Assessment (ACSA)","description":"ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.","timeFrame":"up to 8 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is able to provide written, personally signed, and dated informed consent to participate in the study.\n* Subject is between 18 and 65 years of age.\n* Subject has a primary diagnosis of non-psychotic MDD (single or recurrent).\n* Subject has a MADRS total score 24.\n* Subject who is female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test at the and agrees to comply with any applicable contraceptive requirements of the protocol.\n* Subject is able to swallow a capsule.\n\nExclusion Criteria:\n\n* Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents.\n* Subject who has a lifetime history of treatment resistant depression.\n* Subject has a current co-morbid psychiatric disorder. Excluded are: any significant Axis II disorder (including borderline personality disorder), any bipolar disorder, any current or lifetime psychosis, post traumatic stress disorder, obsessive compulsive disorder, any pervasive development disorder, anorexia nervosa and bulimia nervosa.\n* Subject has been hospitalized (within the last 12 months) for their current MDD episode.\n* Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).\n* Subject has a first degree relative that has been diagnosed with bipolar I disorder.\n* Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder\n* Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.\n* Subject has a concurrent chronic or acute illness or unstable medical condition.\n* Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.\n* Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.\n* Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.\n* Subject has a known family history of sudden cardiac death or ventricular arrhythmia.\n* Subject has glaucoma.\n* Subject has a history of moderate to severe hypertension.\n* Current use of any other medications (including over-the-counter \\[OTC\\], herbal or homeopathic preparations) that have central nervous system effects.\n* Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior.\n* The subject has a known or suspected intolerance, hypersensitivity, or contraindications to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl).\n* Subject has a positive urine drug result.\n* Subject has a body mass index (BMI) of \\<18.5 or \\>40.\n* Subject is female and is pregnant or nursing.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Study Director","affiliation":"Takeda","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Birmingham Research Group","city":"Birmingham","state":"Alabama","zip":"35216","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"AV Institue, Inc.","city":"Carson","state":"California","zip":"90746","country":"United States","geoPoint":{"lat":33.83141,"lon":-118.28202}},{"facility":"University of California, Irvine Child Development Center","city":"Irvine","state":"California","zip":"92612","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"South Coast Clinicals","city":"Norwalk","state":"California","zip":"90650","country":"United States","geoPoint":{"lat":33.90224,"lon":-118.08173}},{"facility":"North County Clinical Research","city":"Oceanside","state":"California","zip":"92056","country":"United States","geoPoint":{"lat":33.19587,"lon":-117.37948}},{"facility":"Pasadena Research Institute, LLC","city":"Pasadena","state":"California","zip":"91106","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Affiliated Research Institute","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Clinical Innovations, Inc.","city":"San Diego","state":"California","zip":"92121","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Sharp Mesa Vista Hospital","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Geriatric and Adult Psychiatry, LLC","city":"Hamden","state":"Connecticut","zip":"06518","country":"United States","geoPoint":{"lat":41.39593,"lon":-72.89677}},{"facility":"Middlexex Hospital Center for Behavioral Health","city":"Middletown","state":"Connecticut","zip":"06457","country":"United States","geoPoint":{"lat":41.56232,"lon":-72.65065}},{"facility":"CNS Clinical Research Group","city":"Coral Springs","state":"Florida","zip":"33067","country":"United States","geoPoint":{"lat":26.27119,"lon":-80.2706}},{"facility":"Emerald Coast Mood & Memory, PA","city":"Fort Walton Beach","state":"Florida","zip":"32547","country":"United States","geoPoint":{"lat":30.42059,"lon":-86.61707}},{"facility":"Florida Clinical Research Center, LLC.","city":"Maitland","state":"Florida","zip":"32751","country":"United States","geoPoint":{"lat":28.62778,"lon":-81.36312}},{"facility":"Suncoast Clinical Research","city":"New Port Richey","state":"Florida","zip":"34652","country":"United States","geoPoint":{"lat":28.24418,"lon":-82.71927}},{"facility":"Compass Research, LLC","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Meridien Research","city":"St. Petersburg","state":"Florida","zip":"33709","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Stedman Clinical Trials","city":"Tampa","state":"Florida","zip":"33613","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Carman Research","city":"Smyrna","state":"Georgia","zip":"30080","country":"United States","geoPoint":{"lat":33.88399,"lon":-84.51438}},{"facility":"American Medical Research, Inc.","city":"Oak Brook","state":"Illinois","zip":"60523","country":"United States","geoPoint":{"lat":41.83281,"lon":-87.92895}},{"facility":"The Davis Clinic","city":"Indianapolis","state":"Indiana","zip":"46260","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Northwest Indiana Center for Clinical Research","city":"Valparaiso","state":"Indiana","zip":"46383","country":"United States","geoPoint":{"lat":41.47309,"lon":-87.06114}},{"facility":"MCM Clinical Research LLC","city":"Florence","state":"Kentucky","zip":"41042","country":"United States","geoPoint":{"lat":38.99895,"lon":-84.62661}},{"facility":"Pharmasite Research, Inc.","city":"Baltimore","state":"Maryland","zip":"21208","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Potomac Grove Clinical Research Center","city":"Gaithersburg","state":"Maryland","zip":"20877","country":"United States","geoPoint":{"lat":39.14344,"lon":-77.20137}},{"facility":"Office of Marc Hertzman, MD","city":"Rockville","state":"Maryland","zip":"20852","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Adams Clinical Trials, LLC","city":"Watertown","state":"Massachusetts","zip":"02472","country":"United States","geoPoint":{"lat":42.37093,"lon":-71.18283}},{"facility":"St. Charles Psychiatric Associates - Midwest Research Group","city":"Saint Charles","state":"Missouri","zip":"63301","country":"United States","geoPoint":{"lat":38.78394,"lon":-90.48123}},{"facility":"Bioscience Research, LLC","city":"Mount Kisco","state":"New York","zip":"10549","country":"United States","geoPoint":{"lat":41.20426,"lon":-73.72708}},{"facility":"Fieve Clinical Research","city":"New York","state":"New York","zip":"10168","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Richmond Behavioral Associates","city":"Staten Island","state":"New York","zip":"10312","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"facility":"Triangle Neuropsychiatry","city":"Durham","state":"North Carolina","zip":"27707","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Rcihard H. Weisler, MD, PA & Associates","city":"Raleigh","state":"North Carolina","zip":"27809","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Community Research","city":"Cincinnati","state":"Ohio","zip":"45227","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Lindner Center of HOPE","city":"Mason","state":"Ohio","zip":"45040","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"SP Research, PLLC","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Summit Research Network (Oregon) Inc.","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Paramount Clinical Research","city":"Bridgeville","state":"Pennsylvania","zip":"15107","country":"United States","geoPoint":{"lat":40.35618,"lon":-80.11006}},{"facility":"Suburban Research Associates","city":"Media","state":"Pennsylvania","zip":"19063","country":"United States","geoPoint":{"lat":39.91678,"lon":-75.38769}},{"facility":"CRI Worldwide LLC","city":"Philadelphia","state":"Pennsylvania","zip":"19139","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Pittsburgh School of Medicine","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Rhode Island Mood & Memory Research Institute","city":"East Providence","state":"Rhode Island","zip":"02914","country":"United States","geoPoint":{"lat":41.81371,"lon":-71.37005}},{"facility":"Clinical Neuroscience Solutions, Inc.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Clinical Research Associates","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"FutureSearch Clinical Trials, LP","city":"Austin","state":"Texas","zip":"78731","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Ericksen Research and Development","city":"Clinton","state":"Utah","zip":"84015","country":"United States","geoPoint":{"lat":41.13967,"lon":-112.0505}},{"facility":"Summit Research Network (Seattle) LLC","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Dr. Alexander McIntyre Inc","city":"Penticton","state":"British Columbia","zip":"V2A 4M4","country":"Canada","geoPoint":{"lat":49.48062,"lon":-119.58584}},{"facility":"Dr. D. McIntosh & Dr. K. Kjernisted Clinical Research Inc.","city":"Vancouver","state":"British Columbia","zip":"V6Z 2L4","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Aggarwal & Associates Ltd.","city":"Brampton","state":"Ontario","zip":"L6T 0G1","country":"Canada","geoPoint":{"lat":43.68341,"lon":-79.76633}},{"facility":"Depression, Mood Disorders and Schizophrenia Treatment Centre","city":"Burlington","state":"Ontario","zip":"L7R 4E2","country":"Canada","geoPoint":{"lat":43.38621,"lon":-79.83713}},{"facility":"Chatham-Kent Clinical Trials Research Center","city":"Chatham","state":"Ontario","zip":"N7M 5L9","country":"Canada","geoPoint":{"lat":42.41224,"lon":-82.18494}},{"facility":"Regional Mental Health Care","city":"London","state":"Ontario","zip":"N6A 4H1","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Anxiety and Mood Disorder Center","city":"Mississauga","state":"Ontario","zip":"L5M 4N4","country":"Canada","geoPoint":{"lat":43.5789,"lon":-79.6583}},{"facility":"Medical Research Associates","city":"Mississauga","state":"Ontario","zip":"L5M 4N4","country":"Canada","geoPoint":{"lat":43.5789,"lon":-79.6583}},{"facility":"A.K. Karan Holdings","city":"Oakville","state":"Ontario","zip":"L6J0B2","country":"Canada","geoPoint":{"lat":43.45011,"lon":-79.68292}},{"facility":"International Sleep Clinic, West Parry Sound Health Centre","city":"Parry Sound","state":"Ontario","zip":"P2A 3A4","country":"Canada","geoPoint":{"lat":45.34732,"lon":-80.03527}},{"facility":"START Clinic for Mood and Anxiety Disorders","city":"Toronto","state":"Ontario","zip":"M4W 2N4","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Univ Health Network, Toronto Western Hospital","city":"Toronto","state":"Ontario","zip":"M5T2S8","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Sleep & Alertness Clinic (Sleep & Alertness Research, Inc.)","city":"Toronto","state":"Ontario","zip":"M6J 3S3","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Manna Research","city":"Toronto","state":"Ontario","zip":"M9W 4L6","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Windsor Regional Hospital-Tayfour Campus","city":"Windsor","state":"Ontario","zip":"N9C 3Z4","country":"Canada","geoPoint":{"lat":42.30008,"lon":-83.01654}},{"facility":"Pierre-Janet Hospital","city":"Gatineau","state":"Quebec","zip":"J8A1K7","country":"Canada","geoPoint":{"lat":45.47723,"lon":-75.70164}},{"facility":"l'Hopital Louis H. Lafontaine","city":"Montreal","state":"Quebec","zip":"H1N 3M5","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Kells Medical Research Group Inc.","city":"Pointe-Claire","state":"Quebec","zip":"H9R 4S3","country":"Canada","geoPoint":{"lat":45.44868,"lon":-73.81669}},{"facility":"ALPHA Recherche Clinique","city":"Québec","state":"Quebec","zip":"G3K 2P8","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Q&T Research Sherbrooke","city":"Sherbrooke","state":"Quebec","zip":"J1H 4J6","country":"Canada","geoPoint":{"lat":45.40008,"lon":-71.89908}},{"facility":"Poliklinika Neuron","city":"Zagreb","zip":"10 000","country":"Croatia","geoPoint":{"lat":45.81444,"lon":15.97798}},{"facility":"Psychiatric Clinic Vrapoe","city":"Zagreb","zip":"10090","country":"Croatia","geoPoint":{"lat":45.81444,"lon":15.97798}},{"facility":"Centro Regiomontano de Investigacion S.C. (CRI)","city":"Monterrey","state":"Nuevo León","zip":"647-10","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}},{"facility":"Hospital Aranda de la Parra","city":"León","zip":"37000","country":"Mexico","geoPoint":{"lat":21.12183,"lon":-101.68253}},{"facility":"Instituto de Infromacion e Investigación en Salud Mental (INFOSAME)","city":"Nuevo León","zip":"64710","country":"Mexico","geoPoint":{"lat":32.4095,"lon":-115.18896}},{"facility":"Consultorio Especializado en Psiquiatria Infantil y Adolescentes","city":"San Luis Potosí City","zip":"78200","country":"Mexico","geoPoint":{"lat":22.15234,"lon":-100.97135}},{"facility":"B & B Investigaciones Medicas S.C.","city":"Sinaloa","zip":"82126","country":"Mexico","geoPoint":{"lat":15.89261,"lon":-92.12896}},{"facility":"Dharma Institute & Research Center","city":"San Juan","zip":"00907","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"INSPIRA Clinical Research","city":"San Juan","zip":"00918","country":"Puerto Rico","geoPoint":{"lat":18.46633,"lon":-66.10572}},{"facility":"Hospital de la Santa Creo l Sant Pau","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari de Bellvitge, Servicio de Psiquiatria","city":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Infanta Leonor","city":"Madrid","zip":"28031","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Fundacion de Alcorcon","city":"Madrid","zip":"28922","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario de Henares","city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Centro de Salud Mental Il la Corredoria","city":"Oviedo","zip":"33011","country":"Spain","geoPoint":{"lat":43.36029,"lon":-5.84476}},{"facility":"Centro Salud Alamedilla Unidad de Salud Mental","city":"Salamanca","zip":"37003","country":"Spain","geoPoint":{"lat":40.96882,"lon":-5.66388}},{"facility":"Complejo hospitalario de Zamora","city":"Zamora","zip":"49021","country":"Spain","geoPoint":{"lat":41.50633,"lon":-5.74456}},{"facility":"Hospital Clinico Universitario Lozano Blesa","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}}]},"referencesModule":{"references":[{"pmid":"27474961","type":"RESULT","citation":"Richards C, McIntyre RS, Weisler R, Sambunaris A, Brawman-Mintzer O, Gao J, Geibel B, Dauphin M, Madhoo M. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Affect Disord. 2016 Dec;206:151-160. doi: 10.1016/j.jad.2016.07.006. Epub 2016 Jul 5."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Antidepressant + Single-blind Placebo","description":"Subjects received unblinded oral, once daily standard antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended-release, or duloxetine hydrochloride) plus oral, once daily placebo (matching SPD489)."},{"id":"FG001","title":"Antidepressant + Double-blind Placebo","description":"Subjects received assigned oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily, double-blind placebo (matching SPD489)."},{"id":"FG002","title":"Antidepressant + Double-blind SPD489","description":"Subjects received assigned oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily SPD489 (Lisdexamfetamine dimesylate optimized among 20, 30, 50, or 70 mg dose)."}],"periods":[{"title":"Antidepressant Lead-in Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Twenty-three subjects were enrolled but not dosed.","numSubjects":"1262"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"896"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"366"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"39"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"96"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Met BP Or Pulse Withdrawal Criteria","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Randomized Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"These subjects were not included in the Safety Analysis Set or Full Analysis Set.","numSubjects":"492"},{"groupId":"FG001","comment":"One subject did not receive at least 1 dose of double-blind treatment.","numSubjects":"202"},{"groupId":"FG002","comment":"One subject did not receive at least 1 dose of double-blind treatment.","numSubjects":"202"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"415"},{"groupId":"FG001","numSubjects":"164"},{"groupId":"FG002","comment":"1 subject completed the study without a Visit 14 MADRS and was not included in the completers set.","numSubjects":"160"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"42"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"10"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Met BP Or Pulse Withdrawal Criteria","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"11"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment (e.g., coming back for any visit, reporting of an adverse event \\[AE\\], or reporting the absence of AEs) after the Augmentation Baseline Visit (Visit 8).","groups":[{"id":"BG000","title":"Antidepressant + Double-blind Placebo","description":"Oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily, double-blind placebo (matching SPD489) for 8 weeks."},{"id":"BG001","title":"Antidepressant + Double-blind SPD489","description":"Oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily SPD489 (Lisdexamfetamine dimesylate optimized among 20, 30, 50, or 70 mg dose) for 8 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"402"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41.8","spread":"12.04"},{"groupId":"BG001","value":"42.2","spread":"12.32"},{"groupId":"BG002","value":"42","spread":"12.17"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"18-55 years","categories":[{"measurements":[{"groupId":"BG000","value":"173"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"343"}]}]},{"title":"56-65 years","categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"59"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"262"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"140"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","lowerLimit":"-7.6","upperLimit":"-4.9"},{"groupId":"OG001","value":"-6.1","lowerLimit":"-7.5","upperLimit":"-4.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.883","statisticalMethod":"Mixed- effects Model for Repeat Measures","paramType":"Difference in LS Mean","paramValue":"0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.7","ciUpperLimit":"2.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.96"}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks","description":"Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","lowerLimit":"-5.3","upperLimit":"-3.3"},{"groupId":"OG001","value":"-4.7","lowerLimit":"-5.6","upperLimit":"-3.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.576","statisticalMethod":"Mixed- effects Model for Repeat Measures","paramType":"Difference in LS Mean","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.8","ciUpperLimit":"1.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.69"}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a 25% Response on the MADRS","description":"The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0"},{"groupId":"OG001","value":"74.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a 50% Response on the MADRS","description":"The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5"},{"groupId":"OG001","value":"41.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Remission on the MADRS","description":"MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5"},{"groupId":"OG001","value":"18.5"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline Over Time in MADRS Total Score","description":"MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"Baseline and up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}]}],"classes":[{"title":"Visit 9 (Week 9)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","lowerLimit":"-3.1","upperLimit":"-1.2"},{"groupId":"OG001","value":"-3.4","lowerLimit":"-4.3","upperLimit":"-2.4"}]}]},{"title":"Visit 10 (Week 10)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","lowerLimit":"-4.9","upperLimit":"-2.7"},{"groupId":"OG001","value":"-4.2","lowerLimit":"-5.3","upperLimit":"-3.2"}]}]},{"title":"Visit 11 (Week 11)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","lowerLimit":"-7.2","upperLimit":"-4.8"},{"groupId":"OG001","value":"-5.4","lowerLimit":"-6.6","upperLimit":"-4.2"}]}]},{"title":"Visit 12 (Week 12)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","lowerLimit":"-7.4","upperLimit":"-5.0"},{"groupId":"OG001","value":"-5.6","lowerLimit":"-6.8","upperLimit":"-4.4"}]}]},{"title":"Visit 13 (Week 14)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","lowerLimit":"-8.7","upperLimit":"-6.0"},{"groupId":"OG001","value":"-7.3","lowerLimit":"-8.6","upperLimit":"-6.0"}]}]},{"title":"Visit 14 (Week 16)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","lowerLimit":"-7.6","upperLimit":"-4.9"},{"groupId":"OG001","value":"-6.1","lowerLimit":"-7.5","upperLimit":"-4.8"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)","description":"The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \\[low amount of symptom\\]) to 3 (representing the least favorable response \\[frequent/intense symptom\\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"185"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","lowerLimit":"-3.2","upperLimit":"-1.9"},{"groupId":"OG001","value":"-2.3","lowerLimit":"-2.9","upperLimit":"-1.7"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)","description":"Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"186"}]}],"classes":[{"title":"Physical","categories":[{"measurements":[{"groupId":"OG000","value":"0.69","lowerLimit":"-0.39","upperLimit":"1.77"},{"groupId":"OG001","value":"-0.81","lowerLimit":"-1.89","upperLimit":"0.28"}]}]},{"title":"Mental","categories":[{"measurements":[{"groupId":"OG000","value":"5.59","lowerLimit":"3.93","upperLimit":"7.25"},{"groupId":"OG001","value":"6.5","lowerLimit":"4.84","upperLimit":"8.16"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)","description":"The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"184"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"4.9","upperLimit":"9.5"},{"groupId":"OG001","value":"7.0","lowerLimit":"4.7","upperLimit":"9.3"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impressions - Global Improvement (CGI-I)","description":"Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"199"}]}],"classes":[{"title":"Improved","categories":[{"measurements":[{"groupId":"OG000","value":"53.3"},{"groupId":"OG001","value":"55.3"}]}]},{"title":"Not Improved","categories":[{"measurements":[{"groupId":"OG000","value":"46.2"},{"groupId":"OG001","value":"44.7"}]}]},{"title":"Not Assessed","categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Columbia Suicide Severity Rating Scale (C-SSRS)","description":"C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"201"}]}],"classes":[{"title":"≥1 postive suicidal ideation","categories":[{"measurements":[{"groupId":"OG000","value":"7.0"},{"groupId":"OG001","value":"7.0"}]}]},{"title":"≥1 suicidal attempt","categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Amphetamine Cessation Symptom Assessment (ACSA)","description":"ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.","populationDescription":"Full Analysis Set: Subjects who took at least 1 dose of randomized investigational product and who had at least 1 valid primary efficacy measurement of the MADRS total score after the Augmentation Baseline Visit (Visit 8).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"up to 8 weeks","groups":[{"id":"OG000","title":"Antidepressant + Placebo","description":"Antidepressant + Placebo: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks."},{"id":"OG001","title":"Antidepressant + SPD489","description":"Antidepressant + SPD489 (Lisdexamfetamine dimesylate): Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) oral, once daily + SPD489 (optimized as a 20, 30, 50, or 70 mg dose, oral, once daily), for 8 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"183"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"10.71"},{"groupId":"OG001","value":"14.7","spread":"10.94"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Antidepressant + Placebo","description":"Oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release, or duloxetine hydrochloride) plus oral, once daily, double-blind placebo (matching SPD489).","seriousNumAffected":5,"seriousNumAtRisk":201,"otherNumAffected":54,"otherNumAtRisk":201},{"id":"EG001","title":"Antidepressant + SPD489","description":"Oral, once daily antidepressant therapy (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride), plus oral, once daily SPD489 (Lisdexamfetamine dimesylate optimized among 20, 30, 50 or 70 mg dose).","seriousNumAffected":3,"seriousNumAtRisk":201,"otherNumAffected":70,"otherNumAtRisk":201}],"seriousEvents":[{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201}]},{"term":"Appendicitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":201}]},{"term":"Wound infection","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":201},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":201}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201}]},{"term":"Syncope","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":201}]},{"term":"Major depression","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201}]},{"term":"Appendicectomy","organSystem":"Surgical and medical procedures","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":201},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":201}]}],"otherEvents":[{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":201},{"groupId":"EG001","numEvents":19,"numAffected":19,"numAtRisk":201}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":201},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":201}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":201},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":201}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":201},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":201}]},{"term":"Headache","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":28,"numAffected":21,"numAtRisk":201},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":201}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":201},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":201}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually."},"pointOfContact":{"title":"Study Director","organization":"Shire","email":"ClinicalTransparency@shire.com","phone":"+1 866 842 5335"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069478","term":"Lisdexamfetamine Dimesylate"}],"ancestors":[{"id":"D003913","term":"Dextroamphetamine"},{"id":"D000661","term":"Amphetamine"},{"id":"D000662","term":"Amphetamines"},{"id":"D010627","term":"Phenethylamines"},{"id":"D005021","term":"Ethylamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}